Top Markets
Coin of the day
VivoSim Labs, Inc. VivoSim Labs, Inc.

VivoSim Labs, Inc.

VIVS
Rangering i aksjer #38702
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company,... VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Aksjekurs
$0.3222
Markedsverdi
$827.61K
Endring (1 dag)
-1.80%
Endring (1 år)
-82.10%
Land
US
Handel VivoSim Labs, Inc. (VIVS)

Kategori

EPS for VivoSim Labs, Inc. (VIVS)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til VivoSim Labs, Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for VivoSim Labs, Inc. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter